Categories Uncategorized

Exploring How Psilocybin Affects Self-Perception

Researchers from Montclair State University recently dived into multitudes of social media posts to try and understand how psilocybin, the main psychedelic element within magic mushrooms, affects an individual’s self-perception. Published in the “Journal of Psychedelic Studies,” the recent study sought to understand how psychedelics, specifically psilocybin, affect self-perception and self-recognition.

Psychedelics such as psilocybin have attracted considerable attention in recent years, thanks to a growing body of scientific studies and anecdotal reports of their efficacy against a myriad of mental conditions.  Scientific literature on psychedelics states that they can treat the symptoms of debilitating mental disorders, including post-traumatic stress disorder (PTSD), anxiety and treatment-resistant depression, especially when they are paired with traditional talk therapy.

However, although several studies have found that various psychedelics have some mental-health benefits, researchers still don’t have a full understanding of how psychedelics affect people’s mental states or deliver their benefits. For the study, self-perception referred to how an individual views themselves in light of emotions, characteristics and qualities while self-recognition is the ability/inability to identify oneself correctly using mirror reflection, or self-reflection.

Led by Montclair State University’s Sam Elias, the research team found that psychedelic users go through a considerable range of experiences while they are under the influence. The researchers searched for Reddit posts with the keywords “shroom mirror” or psychedelic mirror, then screened the relevant posts against the inclusion criteria such as other substances used, how they described the mirror-reflection experience and explicit mentions of ingesting psilocybin.

After identifying relevant excerpts related to psilocybin experiences, the research team divided the posts into 15 groupings based on their tone and content. Team members then analyzed each category’s percentage or frequency to determine the number of times certain phrases were mentioned in each category. They then leveraged statistical tests while comparing the categories associated with self-recognition and self-perception.

Self-recognition covers the ”real self,” which is an ability to recognize oneself correctly, vs. the “unreal self,” which an inability to recognize oneself correctly. Self-perception, on the other hand, covers ”positive affect, negative affect and neutral affect.

The team found 89 posts with 775 excerpts out of a total of 486 texts meeting the inclusion requirements for the study.

Researchers did not discover a statistically notable difference between negative affect and positive affect, suggesting that magic mushrooms tend to boost a positive perception of oneself in users. However, the research team acknowledged that the study was limited by its reliance on self-reported Reddit posts. Future studies on how psilocybin affects self-perception will require more control as well as clinical study methods to study how the psychedelic affects self-perception as well as self-recognition via mirror reflections.

As companies such as Compass Pathways PLC (NASDAQ: CMPS) carry on with their R&D programs on psilocybin and other hallucinogens, we could gain more insights into how these substances affect not only perceptions of self but also how they impact other aspects of one’s mental state.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

2 months ago